Breast Cancer Research and Treatment

, Volume 21, Issue 2, pp 111–119 | Cite as

pS2 expression in primary breast carcinomas: Relationship to clinical and histological features and survival

  • Ann D. Thor
  • Frederick C. Koerner
  • Susan M. Edgerton
  • William C. Wood
  • Michael A. Stracher
  • Laurent H. Schwartz
Report

Summary

pS2 protein expression has been reported to have prognostic significance in human breast carcinomas and to correlate with estrogen receptor positivity, although these findings have not been confirmed by all investigators. pS2 positivity was compared to various clinical and histologic parameters in a retrospective study of 290 patients (median follow-up 7.2 years) and significantly correlated with tumor grade and estrogen receptor content (p=0.001 and p=0.0007, respectively). Significant associations between pS2 positivity and lymph node metastases, T stage, histologic tumor type, and patient age were not observed. Univariate and multivariate analyses (controlling for estrogen receptor content, T and N stage) of the patient population at large showed that pS2 positivity was not predictive of disease-free or overall survival. Univariate analysis of lymph node negative patients demonstrated that both pS2 and estrogen receptor positivity were significantly associated with a better outcome. Multivariate analysis of these patients, however, showed that only estrogen receptor data had independent prognostic significance. This study suggests that immunohistochemical analysis for pS2 protein expression will not contribute additional prognostic information if the estrogen receptor content is known.

Key words

breast cancer estrogen receptor prognosis prognostic factors pS2 
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    McGuire WL, Clark GM: The prognostic role of progesterone receptors in human breast cancer. Semin Oncol 10: 2–6, 1983Google Scholar
  2. 2.
    Fuqua SAW, Blum-Salingaros M, McGuire WL: Induction of the estrogen-regulated ‘24K’ protein by heat shock. Cancer Res 49: 4126–4129, 1989PubMedGoogle Scholar
  3. 3.
    Edwards DP, Adams DJ, McGuire WL: Specific protein synthesis regulated by estrogen in human breast cancer. J Steroid Biochem 15: 247–259, 1981PubMedGoogle Scholar
  4. 4.
    Adams DJ, Hajj H, Bitar KG, Edwards DP, McGuire WL: Purification of an estrogen-regulated breast cancer protein by monoclonal antibody affinity chromatography. Endocrinology 113: 415–417, 1983PubMedGoogle Scholar
  5. 5.
    Landry J, Chretien P, Lambert H, Hickey E, Weber LA: Heat shock resistance conferred by expression of the human HSP27 in rodent cells. J Cell Biol 109: 7–15, 1989PubMedGoogle Scholar
  6. 6.
    McGuire SE, Fuqua SAW, Naylor SL, Helin-Davis DA, McGuire WL: Chromosomal assignments of human 27-KDa heat shock protein gene family. Som Cell Mol Genet 15: 167–171, 1989PubMedGoogle Scholar
  7. 7.
    Henry JA, McCarthy AL, Agnus B, Westley BR, May FEB, Nicholson S, Carins J, Harris AL, Horne CHW: Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer: An immunohistochemical study. Cancer 65: 265–261, 1990PubMedGoogle Scholar
  8. 8.
    Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297–302, 1990PubMedGoogle Scholar
  9. 9.
    Kida N, Yoshimura T, Mori K, Hayashi K: Hormonal regulation of synthesis and secretion of pS2 protein relevant to growth of human breast cancer cells (MCF-7). Cancer Res 49: 3494–3498, 1989PubMedGoogle Scholar
  10. 10.
    Brown AMC, Jeltsch J-M, Roberts M, Chambon P: Activation of pS2 gene transcription is a primary response to estrogen in the human breast cancer cell line MCF-7. Proc Natl Acad Sci USA 81: 6344–6348, 1984PubMedGoogle Scholar
  11. 11.
    Rio M-C, Bellocq J-P, Gairard B, Rasmussen UB, Krust A, Koehl C, Calderoli H, Schiff V, Renaud R, Chambon P: Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogeneerbB2. Proc Natl Acad Sci USA 84: 9243–9247, 1987PubMedGoogle Scholar
  12. 12.
    Nunez A-M, Berry M, Imler JL, Chambon P: The 5′ flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promotor (TPA), the c-Has-ras oncoprotein and the c-jun protein. EMBO J 8: 823–829, 1989PubMedGoogle Scholar
  13. 13.
    Nunez A-M, Jakowlev S, Briand JP, Gaire M, Krust A, Rio M-C, Chambon P: Characterization of the estrogen-induced pS2 protein secreted by the human breast cancer cell line MCF-7. Endocrinology 121: 1759–1765, 1987PubMedGoogle Scholar
  14. 14.
    Jeltsch JM, Roberts M, Schatz C, Garnier JM, Brown AMC, Chambon P: Structure of the human oestrogen-responsive gene pS2. Nucleic Acids Res 15: 1401–1414, 1987PubMedGoogle Scholar
  15. 15.
    Moisan JP, Mattei MG, Mandel JL: Chromosome localization and polymorphism of an oestrogen-inducible gene specifically expressed in some breast cancers. Hum Genet 79: 168–171, 1988PubMedGoogle Scholar
  16. 16.
    Schwartz LH, Koerner F, Edgerton SM, Sawicka JM, Rio M-C, Bellocq J-P, Chambon P, Thor AD: pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res 51: 624–628, 1991Google Scholar
  17. 17.
    Manni A: Hormone receptors and breast cancer. N Engl J Med 309: 1383–1385, 1983PubMedGoogle Scholar
  18. 18.
    McGuire WL, Horwitz KB, Pearson OH, Segaloff A: Current status of estrogen and progesterone receptor in breast cancer. Cancer 39: 2934–2974, 1977PubMedGoogle Scholar
  19. 19.
    Leake R: Receptors and response to endocrine therapy. Reviews on Endocrine Related Cancer 20: 45–49, 1987Google Scholar
  20. 20.
    Raemakers JM, Beex LV, Pieters GF, Smals AG, Benraad TJ, Kloppenborg PW: Progesterone receptor activity and the response to the first endocrine therapy in advanced breast cancer. Eur J Cancer Clin Oncol 23: 443–448, 1987PubMedGoogle Scholar
  21. 21.
    Hartmann WH, Uzello L, Sobin LH, Stalsberg H (eds): Histological Typing of Breast Tumors ed. 2. World Health Organization, Geneva, 1981, pp 15–25Google Scholar
  22. 22.
    Black MM, Opler SR, Speer FI: Survival in breast cancer cases in relation to the structure of the primary tumor and regional lymph node. Surg Gynecol Obstet 100: 543–551, 1955PubMedGoogle Scholar
  23. 23.
    Hsu SM, Raine L, Fanger H: Use of avidin-biotin complex (ABC) in immunoperoxidase techniques: Comparison between ABC and unlabelled antibody (PAP) procedure. J Histochem Cytochem 29: 577–580, 1981PubMedGoogle Scholar
  24. 24.
    SAS Institute Inc. SAS Users Guide: Statistical Version 5th Edition. SAS Institute Inc, Cary NC, 1985, pp956Google Scholar
  25. 25.
    Loveras B, Edgerton S, Thor A: Evaluation ofin vitro bromodeoxyuridine labeling of breast carcinomas with the use of a commercial kit. Am J Clin Pathol 95: 41–47, 1991PubMedGoogle Scholar
  26. 26.
    Beatson GT: On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment with illustrative cases. Lancet ii: 104–107, 1986Google Scholar
  27. 27.
    Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15 (Suppl): 20–25, 1988Google Scholar
  28. 28.
    Ruder AM, Lubin F, Wax Y, Geier A, Alfundary E, Chetrit A: Estrogen and progesterone receptors in breast cancer patients: Epidemiologic characteristics and survival differences. Cancer 64: 196–202, 1989PubMedGoogle Scholar
  29. 29.
    Chevallier B, Heintzmann F, Mosseri V, Dauce JP, Bastit P, Graic Y, Brunelle P, Basuyau JP, Comoz M, Asselain B: Prognostic value of estrogen and progesterone receptors in operable breast cancer: Results of a univariate and multivariate analysis. Cancer 62: 2517–2524, 1988PubMedGoogle Scholar
  30. 30.
    Spyratos F, Hacene K, Tubiana-Hulin M, Pallud C, Brunet M: Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. Eur J Clin Oncol 25: 1233–1240, 1989Google Scholar
  31. 31.
    Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P: Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 10: 7895–7903, 1982PubMedGoogle Scholar
  32. 32.
    Roberts M, Wallace J, Jeltsch J-M, Berry M: The 5′ flanking region of the human pS2 gene mediates its transcriptional activation by estrogen in MCF-7 cells. Biochem Biophys Res Commun 151: 306–313, 1988PubMedGoogle Scholar
  33. 33.
    Foekens JA, Rio M-C, Seguin P, van Putten WLJ, Fauque J, Nap M, Klijn JGM, Chambon P: Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res 50: 3832–3837, 1990Google Scholar
  34. 34.
    Henry JA, Pigott NH, Mallick VK, Nicholson S, Fardon JR, Westley BR, May FEB: pNR-2/pS2 immunohistochemical staining in breast cancer: Correlation with prognostic factors and endocrine response. Br J Cancer 63: 615–622, 1991PubMedGoogle Scholar
  35. 35.
    Fisher B, Redmond C, Fisher ER, Caplan R, and other NSABP contributors: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: Findings from NSABP Protocol B-06. J Clin Oncol 6: 1076–1087, 1988PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1992

Authors and Affiliations

  • Ann D. Thor
    • 4
  • Frederick C. Koerner
    • 4
  • Susan M. Edgerton
    • 4
  • William C. Wood
    • 1
  • Michael A. Stracher
    • 2
  • Laurent H. Schwartz
    • 3
  1. 1.Department of SurgeryMassachusetts General HospitalBostonUSA
  2. 2.Department of Orthopaedic Biomechanics LaboratoryMassachusetts General HospitalBostonUSA
  3. 3.Department of Radiation TherapyMassachusetts General HospitalBostonUSA
  4. 4.Department of Pathology, Cox 5Massachusetts General HospitalBostonUSA

Personalised recommendations